However, the clinical significance of ERBB2 amplification/overexpression in gastric cancer patients is still not clear, because most studies had neither follow-up data nor statistical power for that purpose (David et al, 1992; Nakajima et al, 1999; Takehana et al, 2002; Kimura et al, 2004; Kim et al, 2007). This evidence concerns the gene ERBB2 and gastric cancer.